| [1] |
Ostrom QT, Patil N, Cioffi G, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017[J]. Neuro Oncol, 2020, 22(12 Suppl 2): iv1-iv96.
|
| [2] |
Lombardi G, Della Puppa A, Di Stefano AL, et al. Gliomas[J]. Biomed Res Int, 2014, 2014: 470523.
|
| [3] |
Cai HQ, Wang PF, Zhang HP, et al. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss[J]. J Clin Pathol, 2018, 71(8): 702-707.
|
| [4] |
Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas[J]. Oncotarget, 2012, 3(7): 709-722.
|
| [5] |
Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors[J]. N Engl J Med, 2015, 372(26): 2499-2508.
|
| [6] |
Chan AK, Yao Y, Zhang Z, et al. Combination genetic signature stratifies lower-grade gliomas better than histological grade[J]. Oncotarget, 2015, 6(25): 20885-20901.
|
| [7] |
Brat DJ, Verhaak RG, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas[J]. N Engl J Med, 2015, 372(26): 2481-2498.
|
| [8] |
Leeper HE, Caron AA, Decker PA, et al. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas[J]. Oncotarget, 2015, 6(30): 30295-30305.
|
| [9] |
Haase S, Garcia-Fabiani MB, Carney S, et al. Mutant ATRX: uncovering a new therapeutic target for glioma[J]. Expert Opin Ther Targets, 2018, 22(7): 599-613.
|
| [10] |
李卓,朴月善,张立彦,等. ATRX在胶质瘤诊断及患者预后评估中的应用[J].中华病理学杂志, 2017, 46(10): 690-694.
|
| [11] |
Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis[J]. Acta Neuropathol, 2013, 126(3): 443-451.
|
| [12] |
Mur P, Mollejo M, Hernández-Iglesias T, et al. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade[J]. J Neuropathol Exp Neurol, 2015, 74(3): 241-249.
|
| [13] |
Chaurasia A, Park SH, Seo JW, et al. Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival[J]. J Korean Med Sci, 2016, 31(8): 1208-1214.
|
| [14] |
Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT[J]. Acta Neuropathol, 2017, 133(6): 1001-1016.
|
| [15] |
Ebrahimi A, Skardelly M, Bonzheim I, et al. ATRX immunostaining predicts IDH and H3F3A status in gliomas[J]. Acta Neuropathol Commun, 2016, 4(1): 60.
|
| [16] |
Chatterjee D, Radotra BD, Kumar N, et al. IDH1, ATRX, and BRAFV600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population[J]. Surg Neurol Int, 2018, 9: 29.
|
| [17] |
Cai J, Zhang C, Zhang W, et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors[J]. Oncoscience, 2016, 3(7-8): 258-265.
|
| [18] |
Cai J, Zhu P, Zhang C, et al. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas[J]. Oncotarget, 2016, 7(13): 16384-16395.
|
| [19] |
王轶群,李心国,臧培卓. a-地中海贫血/精神发育迟滞综合征蛋白与中枢神经系统胶质瘤的相关性分析[J].四川医学, 2017, 38(11): 1259-1262.
|
| [20] |
张东旭,曲彦明,张明山,等. WHO Ⅱ级脑胶质瘤患者无进展生存期的影响因素分析[J].中华神经外科杂志, 2019, 35(5): 469-473.
|
| [21] |
朱文标,卢善明,李海南,等.联合IDH1、1p/19q和ATRX对胶质瘤分子分型的临床意义[J].南昌大学学报(医学版), 2020, 60(4): 41-45.
|
| [22] |
Hempel JM, Brendle C, Bender B, et al. Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study[J]. J Neurooncol, 2018, 139(2): 373-381.
|
| [23] |
Hempel JM, Schittenhelm J, Klose U, et al. In vivo molecular profiling of human glioma: gross-sectional observational study using dynamic susceptibility contrast magnetic resonance perfusion imaging[J]. Clin Neuroradiol, 2019, 29(3): 479-491.
|
| [24] |
Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations[J]. Acta Neuropathol, 2012, 124(5): 615-625.
|
| [25] |
Takano S, Ishikawa E, Sakamoto N, et al. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas[J]. Brain Tumor Pathol, 2016, 33(2): 107-116.
|
| [26] |
Burford C, Laxton R, Sidhu Z, et al. ATRX immunohistochemistry can help refine 'not elsewhere classified’ categorisation for grade II/III gliomas[J]. Br J Neurosurg, 2019, 33(5): 536-540.
|
| [27] |
Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma[J]. Nature, 2012, 482(7384): 226-231.
|
| [28] |
Heaphy CM, de Wilde RF, Jiao Y, et al. Altered telomeres in tumors with ATRX and DAXX mutations[J]. Science, 2011, 333(6041): 425.
|
| [29] |
Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma[J]. Oncotarget, 2012, 3(10): 1194-1203.
|